Skip to content

Effect of Resistant Starch (Type-4) on Metabolic Syndrome

Dietary Fiber Intervention in Hutterite Population of South Dakota With and Without Signs of Metabolic Syndrome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01887964
Enrollment
86
Registered
2013-06-27
Start date
2012-03-31
Completion date
2012-10-31
Last updated
2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Keywords

Diabetes, Obesity, Cardiovascular disease, Metabolic syndrome

Brief summary

Metabolic syndrome is a condition characterized by excess body weight, large waist circumference, high cholesterol and glucose in the blood, and hypertension. People with metabolic syndrome are at increased risk for heart diseases. Research shows benefits of regular fiber intake in metabolic syndrome. However, due to altered taste and texture of the high fiber foods, long term intake of fiber is a challenge for metabolic syndrome patients. This study is designed to find if blinded-substitution of regular wheat flour in domestic kitchen with wheat flour enriched by an adaptable type of fiber (resistant starch-4), minimizes metabolic syndrome symptoms. this special type of fiber is also obtained from wheat.

Interventions

OTHERRS4 enriched flour

Wheat flour with 30% resistant starch (type-4)

OTHERControl flour

Wheat flour without resistant starch (type-4)

Sponsors

South Dakota State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

\- Any individual aged 18-80 years

Exclusion criteria

* Pregnant * Lactating * Requires special diets or dietary regimens * On long term antibiotic therapy * Diagnosed with gastrointestinal diseases (Irritable Bowel syndrome, Crohn's disease or Colitis) * Immune compromised * Have cancer

Design outcomes

Primary

MeasureTime frame
Changes in metabolic syndrome risk components26 weeks

Secondary

MeasureTime frameDescription
Changes in anthropometric outcomes26 weeksBody weight, body mass index, systolic and diastolic blood pressure, fat mass and fat-free mass
Changes in blood lipid profile26 weekstotal cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol and triglycerides
Changes in blood glucose indices26 weeksfasting blood glucose, postprandial blood glucose and Hemoglobin-A1C

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026